Generics Bulletin’s Top 50 Ranking For 2021
Compiling All The Data From Our List Of The Top Industry Players
Executive Summary
This article brings you a compilation of all the data from Generics Bulletin’s recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q3 2021
Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.
Stada Begins Work On Romanian Hub
Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.
Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.